Using baseline blood samples, researchers have identified an eight-gene expression signature to predict patient responses to Zytiga plus prednisone or Xtandi.
City of Hope and Texas Oncology are the first customers for Trapelo, a decision support platform from Innovation Insights that involves labs and payors.
